Variable | All participants n = 320 | Survivors n = 257 | Non-survivors n = 63 |
---|---|---|---|
Organ support and additional therapies, n (%) | |||
Mechanical ventilationa | 182 (56.9) | 136 (52.9) | 46 (73.0) |
Invasive mechanical ventilation | 116 (36.2) | 77 (30.0) | 39 (61.9) |
Neuromuscular blocking agents | 17 (5.3) | 13 (5.1) | 4 (6.3) |
Prone positioning | 35 (10.9) | 23 (8.9) | 12 (19.0) |
NO | 17 (5.3) | 13 (5.1) | 4 (6.3) |
ECMO | 6 (1.9) | 3 (1.2) | 3 (4.8) |
Vasopressors | 100 (31.2) | 62 (24.1) | 38 (60.3) |
Renal replacement therapy | 39 (12.2) | 22 (8.6) | 17 (27) |
Steroidsb | 67 (20.9) | 52 (20.2) | 15 (23.8) |
Oseltamivirc | 278 (86.9) | 232 (90.3) | 46 (73.0) |
Length of stay (days), median [IQR] | |||
ICU | 8 [4–15] | 8 [4–15] | 7 [2–15.5] |
Hospital | 15 [8–28] | 16 [9–31] | 10 [3.5–18.5] |